correlation between total tau and gamma/theta CFC nor total ACE test score. This may be attributed to the low sample size or delays between neurodegeneration and subsequent changes in cognition. If gamma/theta CFC is to be considered as an early marker of progressive symptoms, it may also be abnormal in patients with progressive pathophysiology with yet no neurodegeneration, parallel to what is observed in, for instance, PET biomarker studies.
